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Objective: To determine the effects of varying doses of orally administered BPA on indices of 
glucose metabolism. 
Methods: Eleven college students (21.0 6 0.8 years; 24.2 6 3.9 kg/m2) were randomized in a double-
blinded, crossover fashion separated by .1 week to placebo (PL), deuterated BPA at 4 mg/kg body weight 
(BPA-4), and deuterated BPA at 50 mg/kg body weight (BPA-50). Total BPA, glucose, insulin, and 
C-peptide were assessed at baseline, minutes 15, 30, 45, 60, and every 30 minutes for 2 hours in response 
to a glucose tolerance test. 
Results: There was a significant condition 3 time interaction for total BPA (P , 0.001) such that BPA 
increased more rapidly in BPA-50 than BPA-4 and PL (P = 0.003) and increased more rapidly in BPA-4 
than PL (P , 0.001). There were no significant condition 3 time interactions on glucose, insulin, and 
C-peptide. Significant condition main effects were observed for glucose such that BPA-50 was signif-
icantly lower than PL (P = 0.036) and nearly lower for BPA-4 vs PL (P = 0.056). Significant condition 
main effects were observed such that insulin in BPA-50 was lower than BPA-4 (P = 0.021), and C-peptide 
in BPA-50 was lower than BPA-4 (t18 = 3.95; Tukey-adjusted P = 0.003). Glucose, insulin, and C-peptide 
areas under the curve for the 3-hour profile were significantly lower in BPA-50 vs PL (P , 0.05). 
Conclusion: Orally administered BPA protocol appeared feasible and has immediate effects on glucose, 
insulin, and C-peptide concentrations. 
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/). 
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The prevalence of diabetes is well established, affecting .29 million Americans with 90% to 
95% of these individuals diagnosed with type 2 diabetes [1], and linked to several health risks 
including insulin resistance [2, 3] and cardiovascular disease [4]. Clearly, diet, physical 
activity, and genetics play roles in the etiology of type 2 diabetes, but only explain 30% to 
60% of variance [5]. Emerging data suggest the mass industry-produced chemical bisphenol 
A (BPA) may play a role in type 2 diabetes and obesity rates [6–17]. BPA exposure is 
Abbreviations: BPA, bisphenol A; BPA-4, deuterated bisphenol A at 4 mg/kg body weight; BPA-50, deuterated bisphenol A at 50 mg/kg 
body weight; BW, body weight; CONSORT, Consolidated Standards of Reporting Trials; d6-BPA, deuterated 6-bisphenol A; EPA, 
Environmental Protection Agency; HOMA-IR, homeostasis model assessment of insulin resistance; OGTT, oral glucose tolerance 
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widespread, with an estimated 93% of the US population with detectable urine levels [18]. 
The National Health and Nutrition Examination Survey, Nurses’ Health Study II, and other 
cross-sectional data have shown associations between urinary BPA concentrations and type 2 
diabetes [16, 17, 19, 20], prediabetes [21], insulin resistance [22], and hemoglobin A1c [23]. 
BPA appears related to diabetes risk factors independent of weight status and obesity, which 
has also been correlated with urinary BPA levels in some but not all studies [19, 23]. Animal 
and in vitro data suggest that BPA has estrogenic activity [7] and disrupts several pathways 
in the pathogenesis of type 2 diabetes including decreased insulin sensitivity [24], dysre-
gulation of glucose metabolism [25], altered b-cell and hepatic cell functioning [14, 25], and 
altered adiponectin release from adipose tissue [26]. 
Animal feeding studies have shown that long-term consumption of BPA induces glucose 
intolerance, insulin resistance, and ultimately type 2 diabetes [6, 24]. However, in humans, 
evidence linking BPA exposure with diabetes risk is mainly associative in nature [20, 23]. 
Previous well-controlled studies have determined the pharmacokinetics of oral consumption 
of BPA [27–29]. To our knowledge, only one other human study examined the effects of oral 
BPA consumption on indices of glucose metabolism in men and postmenopausal women 
without diabetes and showed that BPA consumption of 50 mg/kg body weight (BW) sup-
pressed insulin and C-peptide concentrations in response to glucose infusion [30]. The ob-
jective of this pilot study was to determine the effects of varying doses of orally administered 
BPA on indices of glucose metabolism in nonobese adults using a randomized, double-
blinded, crossover design. 
1. Materials and Methods 
A. Participants 
Eleven (eight female and three male) young college students from California Polytechnic 
State University in San Luis Obispo, CA, were recruited by voluntary approach or flier on 
campus (Table 1) from 1 September 2016 to 1 March 2018. Eligibility included: (i) 19.7 to 29.9 
(but ,30) kg/m2 BMI; (ii) 20 to 23 (but ,50) years old; (iii) nonsmoking; and (iv) English 
speaking. Exclusion criteria, assessed by a health history questionnaire, included: (i) type 2 or 
type 1 diabetes; (ii) cardiovascular disease or any other metabolic disease/complication; (iii) 
hypertension; and (iv) pregnancy or planned pregnancy. There was no previous history of 
obesity or other chronic disease and no family history of obesity, diabetes, or cardiovascular 
disease (assessed by questionnaire). The Institutional Review Board at California Poly-
technic State University approved the study, and all participants gave verbal and written 
consent. This study was carried out in accordance with the Code of Ethics of the World 
Table 1. Participant Characteristics 
Variable Range 
N 11 (8 female, 3 male) 
Age, y 21.0 (0.8) 20–23 
Height, m 1.7 (0.1) 1.6–1.8 
Weight, kg 70.6 (10.0) 59.0–95.2 
BMI, kg/m2 24.0 (3.4) 19.7–29.9 
Weight status, n (%) 
Normal weight 7 (64) 
Overweight 4 (36) 
Hispanic/Latina, yes/no, n (%) 
Yes 4 (36) 
No 7 (64) 
Data are mean (SD) unless otherwise indicated. 
Abbreviation: BMI, body mass index. 
Medical Association (Declaration of Helsinki). Participants were compensated $30 for 
completing each trial for a total of $90. 
B. Experimental Protocol 
After eligibility was determined, participants completed a demographic questionnaire, and 
weight was collected on digital scale and height by stadiometer. This study adhered to the 
Consolidated Standards of Reporting Trials (CONSORT) guidelines for reporting randomized 
trials [31], using a randomized, double-blinded, balanced, crossover study design. The study 
statistician developed the within-subject randomizations with condition allocations designed 
as A, B, and C and then provided concealed envelopes to research staff. All research staff 
administering BPA to participants and collecting data were blinded to condition allocation. 
Participants arrived at the research center facilities in the morning after an overnight fast (10 
hours) to minimize the effects of recent dietary intake on blood and urine BPA [27]. In the 
morning after the overnight fast, participants consumed 8 ounces of water in a nonplastic 
container. Participants completed a gastrointestinal distress questionnaire [32] and sub-
jective appetite response questionnaire using a visual analog scale [33]. A catheter was then 
placed into a forearm vein, and a fasting blood sample was collected. Participants were then 
randomized, in a double-blinded, balanced, crossover fashion to oral consumption of: (i) 
placebo (PL), (ii) 4 mg/kg BW of deuterated 6-BPA (d6-BPA; BPA-4), and (iii) 50 mg/kg BW of 
d6-BPA (BPA-50). Participants rotated through all three conditions with a minimum of 
1 week among the three visits. Participants were fed a vanilla wafer cookie containing the 
corresponding dose of PL, BPA-4, and BPA-50 using d6-BPA (d6-BPA; CDN Isotopes, Pointe-
Claire, Quebec, Canada), similar to previous pharmacokinetic studies [27, 29], adjusted for 
BW. Single-dosing solutions (10 mg/mL) for BPA-4 and BPA-50 were prepared by dissolving 
d6-BPA in absolute 95% ethanol (Acros Organics, Janssen Pharmaceutical, Beerse, Belgium). 
For PL, d6-BPA was not included in the ethanol solution. To maintain blinding, a research 
assistant not involved in any other aspect of this study made the dosing solutions, which were 
correspondingly labeled A, B, and C. Six to 8 hours before each condition trial, aliquots were 
passed twice through a sterile microfilter to aid in removal of bacteria and placed onto a 
vanilla wafer cookie (18 calories, 2.6 g carbohydrate, 0.8 g fat, and 0.1 g protein), allowing the 
ethanol to dry. The doses of BPA selected in the proposed study were chosen to be consistent 
with safe doses established by the European Food Safety Authority and the US Environ-
mental Protection Agency (EPA). According to the European Food Safety Authority [34] and 
the US EPA [35], a BPA value of 50 mg/kg BW-day (50,000 ng/kg-day) is the tolerable daily 
intake and reference dose considered safe dose throughout a lifetime, although recently the 
European Food Safety Authority has lowered this dose to 4 mg/kg BW-day [36] extrapolated 
from animal data. Blood samples, gastrointestinal distress questionnaire, and subjective 
appetite ratings using a visual analog scale were collected at baseline (prior to consumption of 
the vanilla wafer cookie), minutes 15, 30, 45, and 60, and then every 30 minutes for the next 
2 hours in response to a 75-g oral glucose tolerance test (OGTT; Fisher Scientific, Houston, TX) 
under each of the three conditions. The primary outcome measures were serum total BPA, 
glucose, insulin, C-peptide, proinsulin, 17b-estradiol, and triglyceride concentrations. Sec-
ondary outcomes measures were gastrointestinal distress and subjective appetite ratings. 
Based on CONSORT guidelines, there were no participant harms or unintended effects of the 
three conditions on participants. Besides the vanilla wafer cookie and 75-g glucose drink, 
participants were not provided any other food during the conditions. 
C. Biochemical Analyses 
Venous blood samples were collected in sterile syringes and transferred to vacutainers 
containing sodium fluoride and potassium oxalate for analysis of glucose, EDTA for analysis 
of insulin, C-peptide, and proinsulin, and serum for analysis of total BPA, 17b-estradiol, and 
triglycerides. All samples were refrigerated centrifuged (4°C) at (3000g) for 15 minutes, and 
plasma/serum was aliquoted into polystyrene tubes and stored at 280°C until analysis. 
Quantitative assessment of total BPA (Detroit R&D, Inc., Detroit, MI) [37], insulin (Thermo 
Fisher Scientific, Grand Island, NY) [38], C-peptide (Mercodia, Uppsala, Sweden) [39], 
proinsulin (Mercodia) [40], and 17b-estradiol (Thermo Fisher Scientific) [41] were de-
termined by competitive or sandwich ELISA kits. BPA analysis was consistent with Good 
Laboratory Practice methodological protocols [42–44] that included direct testing of blood 
collection and storage apparatus, controls with high and low concentrations (range 1 pg/mL to 
100,000 pg/mL), and triplicate sample analysis. The limit of detection for total BPA using the 
ELISA kit was 0.5 ng/mL. We assessed total BPA in storage apparatus and in the 75-g glucose 
drink using the established Centers for Disease Control and Prevention protocol [45, 46] by  
using online solid-phase extraction coupled to HPLC-isotope dilution tandem mass spec-
trometry with peak focusing as described previously [47]. Total BPA concentrations were 
nondetectable in all storage apparati and in the 75-g glucose drink. Glucose and triglyceride 
concentrations were assessed using a glucose oxidase method and triglyceride reagent 
(Analox Instruments Ltd, Stourbridge, United Kingdom). 
D. Calculations 
Glucose, insulin, C-peptide, proinsulin, 17b-estradiol, and triglyceride concentrations were 
used to calculate areas under the curve using the trapezoidal method. Homeostasis model 
assessment of insulin resistance (HOMA-IR) and Matsuda Index were calculated as pre-
viously described [48]. 
E. Statistical Analysis 
JMP Pro 13.2.1 (SAS Institute, Cary, NC) was used for statistical analysis of data. Summary 
statistics are reported as mean (SD) for participant characteristics, and for clarity purposes, 
figures are presented as geometric mean without SEs for all outcome measures. Geometric 
means and asymmetric SEs for all serum/blood markers and raw data for gastrointestinal 
distress as well as a CONSORT checklist for randomized trials are deposited in the Digital 
Commons at California Polytechnic State University data repository and freely available for 
download [49]. All other data are available from the corresponding author upon e-mail re-
quest. Nondetectable BPA concentrations were assigned the limit of detection of 0.05 ng/mL 
[50]. All outcome measures were not normally distributed and were log transformed prior to 
analysis. A linear mixed model (repeated measures) was used to examine condition, time, and 
condition 3 time effects on serum total BPA, glucose, insulin, C-peptide, proinsulin, 17b-
estradiol, and triglycerides, adjusting for the covariates study-entry BMI and sex. In sec-
ondary analysis for glucose, insulin, and C-peptide only, significance was further explored by 
comparing the conditions at each single time point in response to the OGTT (minutes 60, 90, 
120, 150, 180) using an analysis of covariance. For area under the curve variables, HOMA-IR, 
and Matsuda Index responses, a linear mixed model for the crossover design was used to 
compare the responses across conditions, adjusting for the covariates study-entry BMI and 
sex. A significance level of a = 0.05 was used. Reported P values are unadjusted unless 
otherwise noted as Tukey honestly significant difference adjusted. All participants completed 
all three conditions with no missing data. 
Our sample size was based on previous pharmacokinetic BPA [27, 29] studies to distin-
guish three different serum total BPA conditions. Using a total BPA concentration max of 
270 ng/mL after consumption of 50 to 100 mg/kg BW of d6-BPA [27, 29], with 11 subjects we 
had .99% power to detect a 256 ng/mL total BPA concentration maximum difference be-
tween oral consumption of 50 mg/kg BW of d6-BPA (BPA-50) and PL using a two-sided t test. 
2. Results 
Serum total BPA maximum concentration of 158 6 50 ng/mL for BPA-50 occurred at 63 6 
11 minutes and a maximum concentration of 25 6 16 ng/mL for BPA-4 at 60 6 13 minutes. 
For serum total BPA concentrations, there was a significant condition main effect and in-
teraction (F2,18 = 46.07, P , 0.001; and F12,178 = 8.20, P , 0.001, respectively). In particular, 
total BPA concentrations in the BPA-50 condition compared with both PL and BPA-4 in-
crease more rapidly at minutes 30 through 180 (Fig. 1) (t178 = 7.65, P , 0.001; and t178 = 3.65, 
P = 0.003, respectively). Also, BPA-4 increased more than PL at the same time points (P , 
0.001). These data suggest that we were successful at administering BPA at different doses to 
increase serum total BPA concentrations. 
There was no significant condition 3 time interaction for glucose, insulin, C-peptide, 
proinsulin, 17b-estradiol, and triglyceride concentrations (P . 0.05; Figs. 2 and 3). 
However, a significant main effect for condition was observed for glucose, indicating that 
glucose was significantly lower in the BPA-50 vs PL (t18 = 2.71; Tukey-adjusted P = 0.036) and 
nearly significant vs BPA-4 (t18 = 2.49; Tukey-adjusted P = 0.056; Fig. 2A). Time-slice post hoc 
unadjusted comparisons of glucose concentrations across treatment conditions were sig-
nificantly different at time 120 (F2,251 = 3.88; P = 0.022) and time 150 (F2,251 = 3.42; P = 0.034). 
In particular, glucose concentrations at time 120 were lower in BPA-50 vs PL (t251 = 2.76; P = 
0.006) and suggestively lower vs BPA-4 (t251 = 1.73; P = 0.084). Glucose concentrations at time 
150 was suggestively lower in BPA-50 vs PL (t251 = 1.76; P = 0.079) and not evidently different 
in BPA-4 vs PL (t251 = 0.78; P = 0.430). A significant condition main effect was also observed 
for insulin (F2,18 = 3.56; P = 0.050), indicating lower insulin concentrations in BPA-50 vs BPA-
4 (t18 = 2.53; Tukey-adjusted P = 0.021; Fig. 2B). For C-peptide concentrations, there was a 
significant condition main effect (F2,18 = 7.84; P = 0.004) such that BPA-50 was significantly 
lower than BPA-4 (t18 = 3.95; Tukey-adjusted P = 0.003; Fig. 2C), but not vs PL (t18 = 1.71; P = 
0.228). For proinsulin, 17b-estradiol, and triglyceride concentrations, there were no sig-
nificant condition main effects or condition by time interactions (P . 0.05; Fig. 3A–3C). 
BPA area under the curve was significantly lower in BPA-50 vs PL and BPA-4 (P , 0.001; 
Table 2), and BPA-4 was significantly lower than PL (P , 0.001; Table 2). Glucose, insulin, 
and C-peptide area under the curve was significantly lower in BPA-50 vs PL and insulin area 
under the curve only vs BPA-4 (P , 0.020; Table 2). There was no significant proinsulin, 17b-
estradiol, and triglyceride area under the curve difference (P . 0.05) between conditions 
(Table 2). There was no significant difference (P , 0.05) among PL, BPA-4, and BPA-50 in 
HOMA-IR (least square mean 6 SEM: 2.07 6 0.26, 2.20 6 0.26, and 2.19 6 0.26, re-
spectively; P = 0.91) and Matsuda Index (5.28 6 0.51, 4.97 6 0.51, and 5.97 6 0.51, re-
spectively; P = 0.28). 
There was no significant condition by time interaction or main effect (P . 0.05) in gas-
trointestinal distress [49] or subjective appetite ratings (data not shown). 
Figure 1. Serum BPA concentrations in response to orally administered PL, BPA-4, and BPA-
50. Values are geometric mean. *BPA-50 significantly (P , 0.05) different than PL and BPA-4 at 
all time points; $BPA-4 significantly (P , 0.05) different than PL and BPA-50 at all time points. 
Figure 2. (A) Plasma glucose concentrations, (B) insulin concentrations, and (C) C-peptide 
concentrations in response to orally administered PL, BPA-4, and BPA-50. Values are 
geometric mean. *BPA-50 condition significantly different than PL condition (P , 0.05); 
$BPA-50 condition significantly different than BPA-4 condition (P , 0.05). 
3. Discussion 
The objective of this pilot study was to determine whether varying doses of orally admin-
istered BPA altered indices of glucose metabolism. Findings demonstrated the feasibility of a 
Figure 3. (A) Plasma proinsulin concentrations, (B) 17b-estradiol concentrations, and (C) 
triglyceride concentrations in response to orally administered PL, BPA-4, and BPA-50. 
Values are geometric mean. 
randomized crossover design, varying dose exposure to BPA, and testing direct effects on 
indices of glucose metabolism in humans. Although there were no noteworthy condition 3 
time interactions on indices of glucose metabolism, considerable condition main effects 
suggested that orally administered BPA at 50 mg/kg BW compared with PL or orally ad-
ministered BPA at 4 mg/kg BW surprisingly lowered glucose, insulin, and C-peptide con-
centrations. Additionally, calculated areas under the curve for glucose, insulin, and C-peptide 
were significantly lower with orally administered BPA at 50 mg/kg BW compared with PL. 
Table 2. Calculated Areas Under the Curve for the 3-H Profile 
PL BPA-4 BPA-50 P Value 
BPA AUC (ng/mL $ min) 56 (12, 258)a 571 (126, 2580)b 10,676 (2319, 49,151)c ,0.001 
Glucose AUC (mmol/L $ min) 1088 (978, 1210)a 1068 (960, 1188)a,b 998 (897, 1110)b 0.017 
Insulin AUC (mIU/mL $ min) 6036 (5263, 6922)a 6044 (5271, 6932)a 5120 (4464, 5871)b 0.011 
C-peptide AUC (pmol/L $ min) 201,637 (171,134, 237,576)a 210,018 (178,247, 247,451)a 181,016 (153,632, 213,280)b 0.003 
Proinsulin AUC (pmol/L $ min) 3143 (2510, 3935) 3078 (2458, 3854) 3339 (2667, 4181) 0.749 
Estradiol AUC (pg/mL $ min) 8744 (5161, 14,814) 9608 (5621, 16422) 8913 (5261, 15,102) 0.873 
TG AUC (mmol/L $ min) 172 (137, 217) 160 (127, 201) 165 (131, 208) 0.612 
Data are geometric mean (95% CI). 
Abbreviations: AUC, area under the curve; Estradiol, 17b-estradiol; TG, triglyceride. 
a,b,cWithin each row, geometric means not sharing a similar letter are significantly different (Tukey adjustment, P , 
0.05). 
Although these data need to be interpreted with some caution given the relatively small 
sample size, they provide evidence in humans that orally administered BPA at the US EPA-
approved safe dose [35] may have an immediate effect on altering indices of glucose 
metabolism in humans. These data, which are consistent with the previous human and 
animal studies [6, 30], provide evidence that the estrogen-mimic BPA may potentially have at 
least some role in b-cell functioning and insulin resistance. 
Previous observational studies have shown positive associations between BPA and indices 
of glucose metabolism and type 2 diabetes incidence [23, 51, 52]. For example, Tai and Chen 
[52] found that urinary BPA levels in the third and fourth quartiles, compared with the 
reference quartile, were significantly associated with increased HbA1c (0.46% and 0.44% 
increase, respectively), fasting glucose levels (0.092 mmol/L and 0.075 mmol/L increase, 
respectively), and doctor-diagnosed type 2 diabetes in men. However, these studies were 
strictly associative in nature, and well-controlled experimental studies are needed to de-
termine the direct effect of orally administered BPA on indices of glucose metabolism and 
insulin resistance. To our knowledge, only one other human study and one animal study had 
assessed the immediate effects of a single oral administration of BPA [6, 30]. Recently, 
Stahlhut et al. [30] showed in men and postmenopausal women without diabetes that oral 
BPA consumption of 50 mg/kg BW lowered insulin and C-peptide concentrations in response 
to glucose infusion. Similarly, Alonso-Magdalena et al. [6] showed that in mice, consumption 
of 10 mg/kg BW of BPA had an acute effect and significantly reduced glycemia (blood glucose 
concentrations) with a concomitant increase in insulin concentrations. However, after 4 days 
of injection of 100 mg/kg BW of BPA (double the high dose used in the current study), mice 
drastically increased glycemia and became hyperinsulinemic. Our results are consistent with 
these studies, showing that immediate oral administration of BPA (50 mg/kg BW) lowered 
glucose, insulin, and C-peptide concentrations and reduced calculated areas under the curve 
for these variables. Surprisingly, there was no concomitant reduction in proinsulin. Previous 
studies have found that in individuals without diabetes, only 10% of proinsulin is converted to 
insulin and may take $3 hours to observe notable changes in proinsulin [53, 54]. Longer-term 
(i.e., .1 day) human studies are needed to examine whether an initial acute decline in glucose 
and insulin is followed by a pattern of elevated glucose and insulin concentrations as seen in 
the prior mouse study [6]. 
Previous pharmacokinetic studies in humans have shown that BPA is rapidly metabolized 
and absorbed with serum total BPA concentrations peaking at ;1 hour after consumption of 
BPA and the majority of BPA recovered in urine within 24 hours [27–29, 55]. In the current 
study, we took advantage of these pharmacokinetic study design models and performed an 
OGTT at peak BPA levels ~60 minutes after consumption of BPA, all the while assessing 
glucose, insulin, and C-peptide concentrations. Even though these previous studies have 
shown that ,1% of BPA consumed is unconjugated (bioactive) [27–29], our data and others 
[30] suggest that the increase in serum total BPA concentrations still has an immediate effect 
on glucose, insulin, and C-peptide concentrations and calculated areas under the curve. 
In the current pilot study, the observed changes in glucose, insulin, and C-peptide con-
centrations in response to an OGTT and calculated areas under the curve at the US EPA 
reference dose have clinical implications, as this is the “safe” dose of BPA exposure 
throughout a lifetime [35]. These data, which are consistent with the one other human and 
animal study, provide evidence that the estrogen mimic BPA may ultimately play at least 
some role in insulin resistance. In support, previous animal data have shown that b-cells 
isolated from BPA-treated mice for 8 days had a greater release of insulin in response to high 
glucose [56]. In the current study, we used an OGTT, which has clinical advantages; however, 
hepatic glucose production and muscle insulin sensitivity are not directly measured. Future 
human studies are needed to determine potential mechanisms using gold standard mea-
surements (e.g., hepatic glucose production via stable isotope infusion, euglycemic-
hyperinsulinemic clamp technique, and glucose rate of disposal) through which BPA may act 
to impact insulin resistance. 
Previous human studies have assessed the pharmacokinetics of a single oral consumption 
of BPA, with a total BPA serum concentration maximum of ;4 ng/mL for each microgram of 
BPA ingested per kilogram of BW (150 to 270 ng/mL) occurring at ;60 minutes [27–29]. The 
current study used a very similar orally administered BPA dosing protocol, and, although the 
study was not intended to assess pharmacokinetics, we similarly observed total BPA con-
centration maximum of 159 ng/mL occurring at ;60 minutes, with no reported gastroin-
testinal distress (assessed by questionnaire) or unintended participant harms (based on 
CONSORT guidelines). The recent oral BPA consumption study by Stahlhut et al. [30] and 
previous pharmacokinetic studies [27–29] also reported no side effects of BPA consumption. 
Thus, taken together, these data suggest that in humans, an orally administered BPA 
protocol, at varying doses, is feasible with no reported side effects. Future large-scale clinical 
trials are needed to determine the effects of BPA on glucose metabolism and cutoffs needed 
for human exposure. 
There are notable strengths and limitations of the current pilot study. We experimentally 
tested a randomized, doubled-blinded, balanced trial, consistent with CONSORT guidelines 
[31], examining varying doses of orally administered BPA on indices of glucose metabolism. 
We chose to assess total serum BPA (and not unconjugated BPA) with a commercially 
available ELISA kit that is historically not as reliable [57]. However, the total BPA con-
centrations observed in the current study were consistent with other pharmacokinetic 
studies by Thayer et al. [27] and Vo¨lkel et al. [29]. Additionally, this study was not specifically 
designed to assess the pharmacokinetics of BPA, which have been reported elsewhere 
[27–29]; rather, an objective was to determine the feasibility of recruiting participants in an 
orally administered BPA protocol on indices of glucose metabolism in which the ELISA total 
BPA kit was able to distinguish among the three conditions (Fig. 1). Also, even though 
participants consumed d6-BPA, we assessed total BPA in serum for only 3 hours and did not 
determine the pharmacokinetics in serum or urine throughout the ensuing days. Thus, it 
remains unclear whether the observed changes in glucose, insulin, and C-peptide would 
persist over several days or induce a relative insulin resistance. Finally, we recruited a 
relatively small, convenient sample of young, nonobese college men and women, and our 
results are not able to tease apart potential weight status differences and sex differences and 
may not be generalizable to individuals with higher baseline BPA exposure [19, 20]. 
4. Conclusion 
An orally administered BPA protocol on indices of glucose metabolism appeared feasible in 
humans with no reported gastrointestinal distress, side effects, or unintended participant 
harms. Furthermore, results from this pilot study and others [30] provide suggestive evidence 
that orally administered BPA at the US EPA-approved [35] safe dose of 50 mg kg BW has 
immediate effects on indices of glucose metabolism in young, nonobese adults. Future larger-
scale clinical randomized trials are needed to confirm these findings using gold standard 
measurements (e.g., hepatic glucose production via stable isotope infusion and insulin 
sensitivity via hyperinsulinemic-euglycemic clamp technique) and determine the effects of 
repeated consumption of BPA over several days in humans. 
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